tag multiple-myeloma 
pharmaphorum
AUGUST 25, 2022
Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.
pharmaphorum
JULY 25, 2022
The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 23, 2022
Here, Richard Staines reports on phase I/II data unveiled at the American Society of Hematology conference that supports further clinical development of inobrodib in multiple myeloma and other blood cancers. CellCentric, a U.K-based Of these patients, seven have been treated at the recommended phase II dose (RP2D) and regimen.
pharmaphorum
JANUARY 11, 2021
The FDA is now due to make a decision on ide-cel as a treatment for multiple myeloma in late March. million price tag. That made things difficult for development partner Bristol-Myers Squibb , which inherited the drug previously known as bb2121 through its acquisition of Celgene late in 2019.
XTalks
DECEMBER 21, 2022
The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 million for a single infusion.
pharmaphorum
MARCH 27, 2022
Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. The post CHMP backs J&J’s myeloma CAR-T therapy Carvykti appeared first on.
XTalks
AUGUST 17, 2020
WT1 is overexpressed in many hematological cancers such as acute myeloid leukemia (AML), multiple myeloma, myeloid dysplastic syndrome (MDS), as well as in solid cancers such as glioblastoma, breast, lung and colorectal cancer. This makes it a tumor-specific antigen and easy to raise an immune attack against.
Expert insights. Personalized for you.
98 
Let's personalize your content